Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 6:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 60 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cervical Carcinoma in Situ Clear all
Completed Phase 3 Interventional

Fenretinide in Treating Patients With Cervical Neoplasia

NCT00003075
View directory record Official record
Conditions
Cervical Cancer, Precancerous Condition
Interventions
Fenretinide, Placebo
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2001
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Oct 10, 2026, 6:57 PM EDT
Recruiting Phase 2 Interventional

Ph II Intraperitoneal Paclitaxel + System Therapy in GI Ca w/Peritoneal Carcinomatosis (STOPGAP-B)

NCT07795749
View directory record Official record
Conditions
Esophageal Carcinoma, Gastric Cancer (Diagnosis), Colorectal Adenocarcinoma, Appendiceal Adenocarcinoma, Small Bowel Adenocarcinoma, Hepatobiliary Carcinoma in Situ
Interventions
Paclitaxel Q2W, Paclitaxcel Q3W
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 10, 2026, 6:57 PM EDT
Terminated Phase 2 Interventional

LIFE-Lung Bronchoscopy in Patients at Risk for Developing Lung Cancer

NCT00260598
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma, Head and Neck Squamous Cell Cancer, Pulmonary Disease, Chronic Obstructive
Interventions
LIFE Bronchoscopy
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 85 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Oct 10, 2026, 6:57 PM EDT
Terminated Phase 1 Interventional

A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer

NCT03735290
View directory record Official record
Conditions
Carcinoma, Squamous Cell of Head and Neck, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Non-small Cell Lung Cancer
Interventions
ilixadencel, Pembrolizumab
Biological · Drug
Lead sponsor
Mendus
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
5
States / cities
Coral Gables, Florida • Iowa City, Iowa • Louisville, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Oct 10, 2026, 6:57 PM EDT
Terminated Phase 1 Interventional

Wild Type p53 Adenovirus for Oral Premalignancies

NCT00410865
View directory record Official record
Conditions
Mouth Cancer
Interventions
INGN 201
Genetic
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 7, 2011 · Synced Oct 10, 2026, 6:57 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention

NCT01192204
View directory record Official record
Conditions
Squamous Cell Carcinoma of Mouth, Intraepithelial Neoplasia
Interventions
10% FBR containing bioadhesive gel, placebo gel
Drug
Lead sponsor
Ohio State University
Other
Eligibility
21 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Louisville, Kentucky • Chapel Hill, North Carolina • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 14, 2015 · Synced Oct 10, 2026, 6:57 PM EDT
Terminated Not applicable Interventional Results available

Photodynamic Therapy Using Porfimer Sodium in Treating Patients With Recurrent Mouth or Throat Dysplasia or Recurrent In Situ Cancer or Stage I Cancer of the Mouth or Throat

NCT00530088
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
porfimer sodium, Photdynamic Therapy (PDT)
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 4, 2014 · Synced Oct 10, 2026, 6:57 PM EDT
Completed Early Phase 1 Interventional

Broccoli Sprout Extract in Preventing Recurrence in Patients With Tobacco-Related Head and Neck Squamous Cell Cancer

NCT03182959
View directory record Official record
Conditions
HNSCC, Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Tobacco-Related Carcinoma, Carcinoma in Situ, Dysplasia, Hyperplasia, Premalignant Lesion
Interventions
Avmacol®
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Oct 10, 2026, 6:57 PM EDT
Completed Not applicable Interventional

Effects of Avmacol® in the Oral Mucosa of Patients Following Curative Treatment for Tobacco-related Head and Neck Cancer

NCT03268993
View directory record Official record
Conditions
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Head and Neck Carcinoma, Head and Neck, Tobacco-Related Carcinoma, Carcinoma in Situ, Dysplasia, Hyperplasia, Premalignant Lesion
Interventions
Avmacol
Dietary Supplement
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 7, 2023 · Synced Oct 10, 2026, 6:57 PM EDT
Not listed Phase 2 Interventional

SGN-00101 in Treating Patients With Cervical Intraepithelial Neoplasia

NCT00060099
View directory record Official record
Conditions
Precancerous Condition
Interventions
HspE7
Biological
Lead sponsor
Dana-Farber/Brigham and Women's Cancer Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 6, 2013 · Synced Oct 10, 2026, 6:57 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer

NCT05463796
View directory record Official record
Conditions
Cancer Risk, Cancer Predisposition Syndrome, Hereditary Cancer Prediction, Childhood Cancer Survivors, Adult Cancer Survivors, IARC Carcinogens, Smoking History, Lung Cancer, Ductal/Lobular Carcinoma, Barrett Esophagus, Pancreatic Precursor Lesions, Colonic Dysplasia/Adenomata, Non-Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis, Cirrhosis, High Grade Prostatic Epithelial Neoplasia, High-grade Bladder Urothelial Dysplasia/Carcinoma in Situ, Adenomatous Hyperplasia, High-risk Oral Precancerous Diseases, Melanocytic Lesion, Adult, Hematologic Malignancy, Lung; Node, Serous Tubal Intraepithelial Carcinoma, Endometrial Intraepithelial Neoplasia, Cervical and Endocervical Carcinoma in Situ, Vulvar Intraepithelial Neoplasia, Nephrogenic Rests, Benign Bone Lesions With Risk of Malignant Degeneration, Giant Cell Tumor, Osteochondroma, Spitz Nevus
Interventions
Samples
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Not listed
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2031
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 10, 2026, 6:57 PM EDT
Terminated Phase 1 Interventional

Photodynamic Therapy Using HPPH in Treating Patients With Recurrent Dysplasia, Carcinoma in Situ, or Stage I Oral Cavity Cancer

NCT00670397
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
HPPH
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Oct 10, 2026, 6:57 PM EDT
Active, not recruiting Phase 2 Interventional

Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia

NCT04712851
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia, Cervical Squamous Cell Carcinoma In Situ, Cervical Squamous Intraepithelial Neoplasia 2
Interventions
Pembrolizumab
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 10, 2026, 6:57 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Feasibility of the Management of Severe Cervical Dysplasia in a Single Visit

NCT00237562
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia
Interventions
Large loop electrosurgical excision
Procedure
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1999
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated May 5, 2006 · Synced Oct 10, 2026, 6:57 PM EDT
Terminated Phase 2 Interventional Results available

IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3

NCT03267680
View directory record Official record
Conditions
Cervical Squamous Cell Carcinoma In Situ, Vulvar High Grade Squamous Intraepithelial Lesion
Interventions
Cyclophosphamide, Indomethacin, IRX-2, Laboratory Biomarker Analysis, Multivitamin, Omeprazole, Placebo, Therapeutic Conventional Surgery
Drug · Biological · Other + 2 more
Lead sponsor
University of Southern California
Other
Eligibility
25 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
2
States / cities
Los Angeles, California • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 13, 2025 · Synced Oct 10, 2026, 6:57 PM EDT
Completed Phase 2 Interventional

Photodynamic Therapy in Treating Patients With Early Esophageal Cancer

NCT00002935
View directory record Official record
Conditions
Esophageal Cancer
Interventions
porfimer sodium
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2007
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Dec 23, 2011 · Synced Oct 10, 2026, 6:57 PM EDT
Completed Phase 2 Interventional Results available

Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia

NCT00081263
View directory record Official record
Conditions
Cervical Carcinoma, Cervical Intraepithelial Neoplasia Grade 2/3, Stage 0 Cervical Cancer
Interventions
Celecoxib, Laboratory Biomarker Analysis, Placebo
Drug · Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
43
States / cities
Tucson, Arizona • Little Rock, Arkansas • Lewes, Delaware + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2017 · Synced Oct 10, 2026, 6:57 PM EDT
Withdrawn Early Phase 1 Interventional

Effect of Curcumin in Treatment of Squamous Cervical Intraepithelial Neoplasias (CINs)

NCT02554344
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia
Interventions
Curcumin
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
21 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 10, 2026, 6:57 PM EDT
Recruiting Phase 1 Interventional

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

NCT06022029
View directory record Official record
Conditions
Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoma, Non-Hodgkin, Mantle Cell Lymphoma, Bladder Cancer, Uveal Melanoma, Recurrent, Cervix Cancer, Carcinoma in Situ, Head and Neck Squamous Cell Carcinoma, Skin Cancer, Metastatic Cancer, Tumor, Solid, Tumor Recurrence
Interventions
ONM-501, Cemiplimab
Drug
Lead sponsor
OncoNano Medicine, Inc.
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
9
States / cities
Los Angeles, California • Tamarac, Florida • Canton, Ohio + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 10, 2026, 6:57 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Topical Imiquimod vs. LEEP for Women With Carcinoma In-situ of the Cervix

NCT02130323
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia
Interventions
Imiquimod, Loop Electrosurgical Excision Procedure
Drug · Procedure
Lead sponsor
United States Naval Medical Center, San Diego
Federal
Eligibility
21 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Oct 10, 2026, 6:57 PM EDT
Terminated Phase 1 Interventional

Zoledronate in Treating Patients With Cervical Intraepithelial Neoplasia 2/3 or 3

NCT00278434
View directory record Official record
Conditions
Cervical Cancer, Precancerous Condition
Interventions
Zoledronate, Placebo (Saline)
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 24, 2017 · Synced Oct 10, 2026, 6:57 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Serum IGF-II and Cancer: Can IGF II Levels be Used to Monitor and Screen Patients Specifically for Cervical Cancer

NCT01371695
View directory record Official record
Conditions
Cervical Cancer, Cervical Intraepithelial Neoplasia II, Cervical Intraepithelial Neoplasia III
Interventions
Not listed
Lead sponsor
Onconix, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 13, 2011 · Synced Oct 10, 2026, 6:57 PM EDT
Recruiting Not applicable Interventional

CONFIRM: Magnetic Resonance Guided Radiation Therapy

NCT04368702
View directory record Official record
Conditions
Gastric Cancer, Invasive Breast Cancer, in Situ Breast Cancer, Mantle Cell Lymphoma, Larynx Cancer, Bladder Cancer
Interventions
Viewray MRIdian® Linac
Radiation
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 10, 2026, 6:57 PM EDT
Completed Phase 1 Interventional

Photodynamic Therapy Using HPPH in Treating Patients With Dysplasia, Cancer in Situ, or Invasive Cancer of the Larynx

NCT00675233
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
HPPH, laser therapy
Drug · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Oct 10, 2026, 6:57 PM EDT